Synthesis and Anticancer Evaluation of 2-{4-[5-(5-Substituted arylpyrimidin-2-yl)-1 H -pyrazol-3-yl]-phenyl}thiazolo[4,5- b ]pyridine Derivatives

Ch. P. Koteswara Rao; T. B. Rao; G. Kali Charan; B. Srinu; S. R. Maturi

doi:10.1134/S1070363219050244

Synthesis and Anticancer Evaluation of 2-{4-[5-(5-Substituted arylpyrimidin-2-yl)-1H-pyrazol-3-yl]-phenyl}thiazolo[4,5-b]pyridine Derivatives

Authors: Koteswara Rao C.P.¹, Rao T.B.¹, Charan G.K.¹, Srinu B.¹, Maturi S.R.¹
Affiliations:
1. Department of Chemistry
Issue: Vol 89, No 5 (2019)
Pages: 1023-1028
Section: Article
URL: https://journals.rcsi.science/1070-3632/article/view/222918
DOI: https://doi.org/10.1134/S1070363219050244
ID: 222918

Cite item

Full Text

Open Access
Restricted Access

Access granted
Restricted Access

Subscription Access

Abstract
About the authors
References
Statistics

Abstract

In the present study a new series of 2-{4-[5-(5-substituted arylpyrimidin-2-yl)-1H-pyrazol-3-yl] phenyl}thiazolo[4,5-b]pyridine derivatives (11a–11j) are synthesized and tested for their anticancer activity against four human cancer cell lines including MCF-7 (breast), A549 (lung), Colo-205 (colon), and A2780 (ovarian) by the MTT assay. Among synthesized compounds, 11b, 11c, 11d, 11g, and 11j exhibit activity higher than the standard drug.